Vistagen Therapeutics (VTGN) Current Leases (2017 - 2025)
Historic Current Leases for Vistagen Therapeutics (VTGN) over the last 12 years, with Q4 2025 value amounting to $617000.0.
- Vistagen Therapeutics' Current Leases rose 232.17% to $617000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $617000.0, marking a year-over-year increase of 232.17%. This contributed to the annual value of $561000.0 for FY2025, which is 200.0% up from last year.
- Latest data reveals that Vistagen Therapeutics reported Current Leases of $617000.0 as of Q4 2025, which was up 232.17% from $597000.0 recorded in Q3 2025.
- In the past 5 years, Vistagen Therapeutics' Current Leases ranged from a high of $640000.0 in Q2 2025 and a low of $364800.0 during Q1 2021
- In the last 5 years, Vistagen Therapeutics' Current Leases had a median value of $509100.0 in 2023 and averaged $503390.0.
- In the last 5 years, Vistagen Therapeutics' Current Leases skyrocketed by 2065.43% in 2021 and then skyrocketed by 152.78% in 2024.
- Over the past 5 years, Vistagen Therapeutics' Current Leases (Quarter) stood at $424100.0 in 2021, then rose by 10.92% to $470400.0 in 2022, then grew by 13.41% to $533500.0 in 2023, then increased by 13.03% to $603000.0 in 2024, then rose by 2.32% to $617000.0 in 2025.
- Its Current Leases was $617000.0 in Q4 2025, compared to $597000.0 in Q3 2025 and $640000.0 in Q2 2025.